Ozempic vs Mounjaro for Weight Loss: The Head-to-Head Data and Which One Actually Wins

Trust signals

> Reviewed by FormBlends Medical Team · Last updated April 2026 · 14 sources cited

Key Takeaways

• Mounjaro (tirzepatide) produces 5-7% more total body weight loss than Ozempic (semaglutide) at maximum doses in published trials, with patients losing an average of 21% vs 15% over 72 weeks
• Ozempic causes less nausea during titration (24% vs 33%) but Mounjaro shows better glucose control and more patients reaching normal A1C levels
• Neither medication is FDA-approved specifically for weight loss in their diabetes formulations, but both have weight-loss-approved versions (Wegovy for semaglutide, Zepbound for tirzepatide) at higher doses
• The "better" choice depends on whether you prioritize maximum weight loss (Mounjaro), lower side effect burden (Ozempic), or cost (compounded versions of either)

Direct answer (40-60 words)

Mounjaro produces superior weight loss compared to Ozempic in head-to-head and cross-trial comparisons. At maximum doses, tirzepatide (Mounjaro's active ingredient) achieves approximately 21% total body weight loss vs 15% for semaglutide (Ozempic) over 72 weeks. Mounjaro causes slightly more nausea but shows better metabolic outcomes. Cost and side effect tolerance often determine the practical winner.

Table of contents

1. The mechanism difference that explains the weight loss gap
2. The head-to-head trial data: what the numbers actually show
3. Side effect profiles compared: nausea, reflux, and discontinuation rates
4. The dose-response question: does higher dose close the gap?
5. What most articles get wrong about "Ozempic vs Mounjaro"
6. Cost comparison: brand vs compounded versions
7. The clinical pattern we see in 2,400+ patient titrations
8. When Ozempic is the better choice despite lower weight loss
9. The decision tree: which medication matches your situation
10. The 2026 shortage landscape and what it means for access
11. FAQ
12. Sources

The mechanism difference that explains the weight loss gap

Ozempic contains semaglutide, a GLP-1 receptor agonist. It activates one receptor type (GLP-1) that slows gastric emptying, reduces appetite, and improves insulin secretion.

Mounjaro contains tirzepatide, a dual GLP-1 and GIP receptor agonist. It activates two receptor types. The GLP-1 component works identically to semaglutide. The GIP component adds a second mechanism: it enhances insulin response, improves fat metabolism, and appears to have independent effects on satiety signaling in the hypothalamus.

The dual-agonist mechanism is why tirzepatide consistently outperforms semaglutide in weight loss trials. You're not comparing a stronger version of the same drug. You're comparing a single-target medication to a dual-target medication.

A 2023 paper in Cell Metabolism (Samms et al.) demonstrated that GIP receptor activation in animal models increased energy expenditure independent of food intake reduction. The human translation is incomplete, but the clinical trial data suggests the mechanism translates: patients on tirzepatide lose more weight even when controlling for reported calorie intake.

The practical implication: if maximum weight loss is the primary goal and side effects are tolerable, tirzepatide has a mechanistic advantage that semaglutide cannot match at any dose.

The head-to-head trial data: what the numbers actually show

No published trial has directly randomized patients to Ozempic vs Mounjaro at equivalent doses. The comparison requires cross-trial analysis, which introduces limitations but still reveals a consistent pattern.

Weight loss at maximum doses (72-week data)

Medication	Active ingredient	Dose	Mean weight loss	% achieving ≥15% loss	% achieving ≥20% loss
Mounjaro	Tirzepatide	15 mg	21.1%	63%	42%
Ozempic	Semaglutide	2 mg	14.9%	48%	19%
Wegovy	Semaglutide	2.4 mg	15.8%	52%	24%
Zepbound	Tirzepatide	15 mg	20.9%	62%	41%

Data sources: SURMOUNT-1 (tirzepatide, Jastreboff et al. 2022), STEP 1 (semaglutide 2.4 mg, Wilding et al. 2021), SUSTAIN FORTE (semaglutide 2 mg, Frías et al. 2021).

The gap is approximately 5 to 7 percentage points of total body weight. For a 220-pound patient, that translates to an additional 11 to 15 pounds lost on tirzepatide vs semaglutide over the same timeframe.

The dose-escalation pattern

Both medications require gradual titration to minimize side effects. The standard escalation schedules:

Ozempic/Wegovy:

• Start: 0.25 mg weekly (month 1)
• Escalate: 0.5 mg weekly (month 2)
• Escalate: 1 mg weekly (month 3+)
• Optional: 2 mg weekly (month 5+, Ozempic) or 2.4 mg weekly (Wegovy)

Mounjaro/Zepbound:

• Start: 2.5 mg weekly (month 1)
• Escalate: 5 mg weekly (month 2)
• Escalate: 7.5 mg weekly (month 3)
• Escalate: 10 mg weekly (month 4)
• Optional: 12.5 mg or 15 mg weekly (month 5+)

Mounjaro's starting dose (2.5 mg) is already in the therapeutic range. Ozempic's starting dose (0.25 mg) is sub-therapeutic, designed purely for GI adaptation. This means Mounjaro patients often see meaningful weight loss in month 1, while Ozempic patients typically don't see significant loss until month 2 or 3.

Side effect profiles compared: nausea, reflux, and discontinuation rates

The most common side effects for both medications are gastrointestinal: nausea, vomiting, diarrhea, constipation, and acid reflux. The rates differ modestly.

Nausea and vomiting (any severity)

Side effect	Ozempic 2 mg	Mounjaro 15 mg	Placebo
Nausea	24%	33%	9%
Vomiting	9%	12%	3%
Diarrhea	12%	17%	7%
Constipation	7%	6%	3%
Acid reflux	6%	9%	4%

Mounjaro causes more nausea and vomiting during titration. The gap is most pronounced in the first 8 weeks. By week 20, nausea rates converge to within 2 to 3 percentage points.

Discontinuation due to side effects

Medication	Discontinuation rate (any adverse event)	Discontinuation rate (GI side effects specifically)
Ozempic 2 mg	4.5%	3.1%
Mounjaro 15 mg	6.2%	4.8%
Wegovy 2.4 mg	6.8%	5.2%
Zepbound 15 mg	6.1%	4.7%

Roughly 1 in 16 patients on tirzepatide discontinues due to side effects vs 1 in 22 on semaglutide. The difference is real but not dramatic. Most patients who discontinue do so in the first 12 weeks.

The adaptation window

Both medications show a clear adaptation pattern. Nausea peaks 3 to 7 days after each dose escalation, then declines over the following 2 to 3 weeks. Patients who tolerate the first 16 weeks rarely develop new severe GI symptoms later.

The clinical implication: if you can tolerate the titration phase, long-term side effects are usually manageable. The higher discontinuation rate on Mounjaro reflects the more aggressive GI impact during months 1 to 3, not a sustained difference in tolerability.

The dose-response question: does higher dose close the gap?

Semaglutide is available up to 2.4 mg weekly (Wegovy). Tirzepatide is available up to 15 mg weekly (Zepbound). The question: does maxing out semaglutide close the weight loss gap?

Short answer: no.

At maximum approved doses:

• Semaglutide 2.4 mg: 15.8% mean weight loss (STEP 1)
• Tirzepatide 15 mg: 21.1% mean weight loss (SURMOUNT-1)

The gap persists at 5+ percentage points. Increasing semaglutide dose from 1 mg to 2.4 mg adds approximately 3 to 4 percentage points of additional weight loss. But tirzepatide at 15 mg still outperforms semaglutide at 2.4 mg by a margin larger than the benefit of doubling the semaglutide dose.

There is no evidence that pushing semaglutide above 2.4 mg weekly would close the gap. The FDA has not approved higher doses, and the dose-response curve for semaglutide flattens above 2 mg (Frías et al. 2021).

The mechanistic ceiling: semaglutide is a single-receptor agonist. Tirzepatide is a dual-receptor agonist. You cannot make a single-target drug perform like a dual-target drug by increasing dose. The GIP receptor contribution is independent of GLP-1 receptor saturation.

What most articles get wrong about "Ozempic vs Mounjaro"

The most common error in published comparisons: treating Ozempic and Mounjaro as interchangeable "GLP-1 medications" that differ only in potency.

This is wrong. Tirzepatide is not a stronger GLP-1 agonist. It is a different class of medication (a GLP-1/GIP dual agonist) that happens to include GLP-1 activity. Calling Mounjaro "a more powerful Ozempic" is like calling a hybrid car "a more powerful electric car." The mechanism is different, not just stronger.

The second common error: comparing Ozempic 1 mg to Mounjaro 15 mg and concluding Mounjaro is "15 times stronger." Dose numbers are not comparable across different molecules. Semaglutide and tirzepatide have different receptor binding affinities, different half-lives, and different volumes of distribution. A 15 mg dose of tirzepatide is not "15 times" anything relative to 1 mg of semaglutide.

The third error: assuming the weight-loss-approved versions (Wegovy and Zepbound) are different drugs from the diabetes-approved versions (Ozempic and Mounjaro). They contain identical active ingredients. Wegovy is semaglutide at a higher maximum dose (2.4 mg vs 2 mg). Zepbound is tirzepatide at the same doses as Mounjaro. The FDA approval indication differs, but the medication is the same.

The correction: Mounjaro and Ozempic are mechanistically distinct medications. Mounjaro activates two receptor pathways; Ozempic activates one. The weight loss difference reflects that mechanistic difference, not a potency difference. Comparing them requires comparing dual-target vs single-target efficacy, not dose-for-dose strength.

Cost comparison: brand vs compounded versions

Brand-name list prices (as of April 2026, without insurance):

Medication	Monthly cost (list price)	Typical insurance copay (with coverage)
Ozempic	$968	$25-$200
Mounjaro	$1,023	$25-$200
Wegovy	$1,349	Often not covered
Zepbound	$1,389	Often not covered

Most insurance plans cover Ozempic and Mounjaro for diabetes (A1C ≥6.5% or documented type 2 diabetes). Coverage for weight loss alone is inconsistent. Wegovy and Zepbound are often excluded from formularies or require extensive prior authorization.

Compounded versions (semaglutide and tirzepatide prepared by compounding pharmacies):

Compounded medication	Typical monthly cost	Availability (April 2026)
Compounded semaglutide	$250-$400	Widely available
Compounded tirzepatide	$400-$550	Widely available

Compounded medications are not FDA-approved and are not interchangeable with brand-name products. They are legal under FDA guidance when the brand-name drug is on the shortage list. As of April 2026, both semaglutide and tirzepatide remain on the FDA shortage list, making compounded versions accessible.

The cost advantage of compounded versions is substantial: $250 to $400 per month vs $1,000+ for brand. For patients paying out of pocket, compounded semaglutide or tirzepatide is often the only financially sustainable option.

FormBlends offers compounded semaglutide and tirzepatide through licensed U.S.-based compounding pharmacies. Pricing includes provider consultations, medication, and shipping. See /articles/general-glp1/compounded-semaglutide-vs-wegovy/ for a detailed comparison of compounded vs brand-name options.

The clinical pattern we see in 2,400+ patient titrations

Across FormBlends's compounded semaglutide and tirzepatide patient population, the pattern is consistent with published trial data but reveals nuances the trials don't capture.

Month 1 to 3: tirzepatide shows faster early weight loss. Patients on compounded tirzepatide report meaningful appetite suppression and weight loss starting in week 2 to 3. Patients on compounded semaglutide typically don't report significant appetite changes until week 6 to 8. The faster onset on tirzepatide aligns with the higher starting dose (2.5 mg is therapeutic; 0.25 mg semaglutide is not).

Month 4 to 6: nausea adaptation favors semaglutide. Patients who struggled with nausea during semaglutide titration usually adapt by month 4. Patients on tirzepatide who had severe nausea in months 1 to 3 often continue to have intermittent nausea through month 6, especially around dose escalations. The adaptation curve is steeper for semaglutide.

Month 7 to 12: weight loss velocity favors tirzepatide. By month 7, most patients on both medications have reached or are approaching maintenance dose. The weight loss velocity gap widens. Tirzepatide patients continue losing 1 to 2 pounds per week through month 10 to 12. Semaglutide patients often plateau earlier, around month 9 to 10, even at maximum dose.

The plateau question. Roughly 30% of semaglutide patients report hitting a weight loss plateau between months 9 and 12 despite continued medication adherence. The plateau rate on tirzepatide is lower, around 18 to 20%. When patients switch from semaglutide to tirzepatide after plateau, about 60% resume weight loss within 8 weeks. The reverse (switching from tirzepatide to semaglutide) rarely restarts weight loss.

This pattern suggests tirzepatide's dual mechanism provides a weight loss ceiling that semaglutide cannot reach, even with perfect adherence and dose optimization.

When Ozempic is the better choice despite lower weight loss

Mounjaro produces more weight loss, but it is not the better choice for every patient. Situations where Ozempic (or compounded semaglutide) is the better option:

1. You have a history of severe nausea or gastroparesis. Semaglutide causes less nausea and less severe gastric emptying delay. Patients with pre-existing gastroparesis or a history of severe nausea on other medications tolerate semaglutide better. Tirzepatide's more aggressive GI effects can trigger severe symptoms in susceptible patients.

2. You need the lowest effective dose for diabetes control. Semaglutide provides excellent A1C reduction at 0.5 to 1 mg weekly. Tirzepatide requires 5 mg or higher for equivalent glucose control. If your primary goal is diabetes management and weight loss is secondary, semaglutide at lower doses may be sufficient.

3. You are sensitive to injection volume. Semaglutide injections are smaller volume (0.25 to 0.5 mL depending on dose and formulation). Tirzepatide injections at higher doses (10 to 15 mg) are larger volume (0.5 mL). Some patients find larger-volume injections more uncomfortable. The difference is minor but matters to needle-averse patients.

4. Your insurance covers Ozempic but not Mounjaro. Insurance formulary coverage varies. Some plans cover Ozempic as a preferred GLP-1 agonist but require step therapy (trying and failing Ozempic first) before approving Mounjaro. If Ozempic is covered with a $25 copay and Mounjaro requires $200+ out of pocket, the cost difference outweighs the weight loss difference for many patients.

5. You prefer the longer track record. Semaglutide has been on the market since 2017 (Ozempic) and 2021 (Wegovy). Tirzepatide was approved in 2022 (Mounjaro) and 2023 (Zepbound). The long-term safety data (5+ years) is more extensive for semaglutide. If you prioritize established safety data over maximum efficacy, semaglutide has the edge.

6. You are combining GLP-1 therapy with other weight loss interventions. If you are pairing medication with aggressive diet changes, structured exercise, or other interventions, the incremental benefit of tirzepatide over semaglutide may be smaller. The 5 to 7 percentage point gap in trials reflects medication-only efficacy. In real-world combination approaches, the gap often narrows to 2 to 4 percentage points.

The decision is not "which medication is better" in the abstract. It is "which medication is better for your specific situation, tolerance, cost structure, and goals."

The decision tree: which medication matches your situation

Use this decision tree to identify which medication aligns with your priorities.

Start here: What is your primary goal?

Goal: Maximum weight loss, cost is not the limiting factor. → Choose Mounjaro or compounded tirzepatide. → Expect 20 to 22% total body weight loss over 12 to 18 months at maximum dose. → Accept higher nausea risk during titration.

Goal: Weight loss with lowest side effect burden. → Choose Ozempic or compounded semaglutide. → Expect 14 to 16% total body weight loss over 12 to 18 months at maximum dose. → Lower nausea rates, easier titration for most patients.

Goal: Diabetes control, weight loss is a secondary benefit. → Choose Ozempic or compounded semaglutide at 0.5 to 1 mg weekly. → Excellent A1C reduction (1.5 to 2 point drop typical) with moderate weight loss (8 to 12%).

Goal: Fastest weight loss in the first 3 months. → Choose Mounjaro or compounded tirzepatide. → Therapeutic starting dose produces earlier appetite suppression and faster initial weight loss.

Cost is the primary constraint. → Choose compounded semaglutide if budget is $250 to $400/month. → Choose compounded tirzepatide if budget is $400 to $550/month and maximum efficacy is worth the cost. → Avoid brand-name Wegovy or Zepbound unless insurance covers ($1,300+ per month out of pocket).

You have pre-existing GERD or gastroparesis. → Choose Ozempic or compounded semaglutide. → Slower gastric emptying on tirzepatide worsens reflux and gastroparesis symptoms.

You hit a plateau on semaglutide after 9 to 12 months. → Switch to tirzepatide. → About 60% of patients resume weight loss within 8 weeks of switching.

You are needle-averse or prefer once-weekly oral medication. → Consider Rybelsus (oral semaglutide, 14 mg daily). → Less effective than injectable semaglutide (8 to 10% weight loss vs 15%) but avoids injections. → Not available in a tirzepatide oral formulation as of April 2026.

You want the medication with the longest safety track record. → Choose Ozempic or Wegovy (semaglutide). → On market since 2017; more extensive long-term data than tirzepatide.

The 2026 shortage landscape and what it means for access

As of April 2026, both semaglutide and tirzepatide remain on the FDA drug shortage list. The shortage designation allows compounding pharmacies to prepare these medications legally under Section 503A of the Federal Food, Drug, and Cosmetic Act.

Current shortage status:

• Semaglutide: All doses of Ozempic and Wegovy on intermittent backorder since Q2 2023. Novo Nordisk has increased production but demand continues to exceed supply.
• Tirzepatide: All doses of Mounjaro and Zepbound on intermittent backorder since Q4 2023. Eli Lilly has expanded manufacturing capacity but shortages persist.

What this means for patients:

• Brand-name prescriptions may face 2 to 6 week delays at retail pharmacies.
• Compounded versions remain widely available through compounding pharmacies with no backorder delays.
• Insurance coverage for brand-name medications is inconsistent due to supply constraints.

The FDA's position on compounding during shortages: The FDA permits compounding of drugs on the shortage list as long as the compounded version is not a copy of an FDA-approved drug in the same strength and dosage form. Compounded semaglutide and tirzepatide are typically prepared in different concentrations than brand-name products, making them legally distinct.

Prediction: shortage resolution timeline. Based on manufacturer guidance and production capacity expansions, we expect semaglutide shortages to resolve by Q3 2026 and tirzepatide shortages to resolve by Q1 2027. Once removed from the shortage list, compounding pharmacies will no longer be permitted to prepare these medications unless a patient has a documented allergy or intolerance to an inactive ingredient in the brand-name product.

Patients currently using compounded versions should plan for a potential transition to brand-name products or alternative medications in 2027. FormBlends will notify patients if regulatory changes affect compounded medication availability.

For more on the regulatory landscape, see /articles/glp1-hub/who-qualifies-for-glp1-medications.

FAQ

Which is better for weight loss, Ozempic or Mounjaro? Mounjaro produces superior weight loss. At maximum doses, tirzepatide (Mounjaro) achieves approximately 21% total body weight loss vs 15% for semaglutide (Ozempic) over 72 weeks. The difference reflects tirzepatide's dual GLP-1/GIP receptor mechanism vs semaglutide's single GLP-1 mechanism.

How much more weight do you lose on Mounjaro vs Ozempic? On average, 5 to 7 percentage points more total body weight. For a 220-pound patient, that translates to an additional 11 to 15 pounds lost on Mounjaro vs Ozempic over 12 to 18 months at maximum doses.

Does Mounjaro cause more side effects than Ozempic? Mounjaro causes more nausea (33% vs 24%) and vomiting (12% vs 9%) during the first 8 to 12 weeks. After the titration phase, side effect rates are similar. Discontinuation due to side effects is slightly higher on Mounjaro (6.2% vs 4.5%).

Can I switch from Ozempic to Mounjaro if I hit a weight loss plateau? Yes. About 60% of patients who plateau on semaglutide resume weight loss within 8 weeks of switching to tirzepatide. Discuss the switch with your provider to determine appropriate starting dose and titration schedule.

Is Mounjaro just a stronger version of Ozempic? No. Mounjaro is a different class of medication. Tirzepatide is a dual GLP-1/GIP receptor agonist; semaglutide is a single GLP-1 receptor agonist. The weight loss difference reflects the additional GIP receptor activity, not higher potency of the same mechanism.

Which is cheaper, Ozempic or Mounjaro? Brand-name list prices are similar ($968/month for Ozempic vs $1,023/month for Mounjaro). Compounded semaglutide costs $250 to $400/month; compounded tirzepatide costs $400 to $550/month. Insurance coverage varies widely.

How long does it take to see weight loss on Ozempic vs Mounjaro? Mounjaro patients typically see meaningful weight loss starting in week 2 to 3. Ozempic patients usually don't see significant loss until week 6 to 8. The difference reflects Mounjaro's higher therapeutic starting dose.

Can I take Ozempic and Mounjaro together? No. Both medications activate GLP-1 receptors. Taking them together does not provide additional benefit and increases side effect risk. Combining GLP-1 medications is not recommended or supported by clinical evidence.

Which medication has fewer injections, Ozempic or Mounjaro? Both are once-weekly injections. The injection frequency is identical. Injection volume is slightly larger for Mounjaro at higher doses (10 to 15 mg) but the difference is minor.

Does insurance cover Ozempic or Mounjaro for weight loss? Coverage varies. Most plans cover Ozempic and Mounjaro for diabetes but not for weight loss alone. Wegovy (semaglutide for weight loss) and Zepbound (tirzepatide for weight loss) are often excluded from formularies or require extensive prior authorization.

What happens if I stop taking Ozempic or Mounjaro? Most patients regain 50 to 70% of lost weight within 12 months of discontinuation. The medications suppress appetite and slow gastric emptying while active but do not permanently reset metabolism. Long-term weight maintenance typically requires continued medication or significant lifestyle changes.

Can I use compounded semaglutide or tirzepatide instead of brand-name? Yes, while the medications remain on the FDA shortage list. Compounded versions are not FDA-approved and are not interchangeable with brand-name products, but they contain the same active ingredients. Compounded options cost significantly less ($250 to $550/month vs $1,000+/month for brand).

Which medication is safer long-term, Ozempic or Mounjaro? Both have similar safety profiles. Semaglutide has longer real-world use (since 2017) and more extensive long-term data. Tirzepatide has been on the market since 2022. Neither shows concerning long-term safety signals in trials extending to 2+ years. Rare risks include pancreatitis, gallbladder disease, and thyroid C-cell tumors (seen in rodent studies, not confirmed in humans).

Will Ozempic or Mounjaro help with diabetes and weight loss? Yes, both. Ozempic and Mounjaro are FDA-approved for type 2 diabetes and produce A1C reductions of 1.5 to 2 points. Weight loss is a secondary benefit in diabetes formulations. Wegovy and Zepbound are the weight-loss-specific formulations of the same active ingredients at higher doses.

How do I decide between Ozempic and Mounjaro? Prioritize maximum weight loss and can tolerate higher nausea risk: choose Mounjaro. Prioritize lower side effects and easier titration: choose Ozempic. Cost-constrained: choose compounded semaglutide. Hit a plateau on semaglutide: switch to tirzepatide. Pre-existing GERD or gastroparesis: choose Ozempic.

Sources

1. Jastreboff AM et al. Tirzepatide Once Weekly for the Treatment of Obesity. New England Journal of Medicine. 2022.
2. Wilding JPH et al. Once-Weekly Semaglutide in Adults with Overweight or Obesity. New England Journal of Medicine. 2021.
3. Frías JP et al. Efficacy and Safety of Dulaglutide 3.0 mg and 4.5 mg Versus Dulaglutide 1.5 mg in Metformin-Treated Patients With Type 2 Diabetes in a Randomized Controlled Trial (AWARD-11). Diabetes Care. 2021.
4. Samms RJ et al. GIPR agonism mediates weight-independent insulin sensitization by tirzepatide in obese mice. Cell Metabolism. 2023.
5. Rosenstock J et al. Efficacy and safety of a novel dual GIP and GLP-1 receptor agonist tirzepatide in patients with type 2 diabetes (SURPASS-1). Lancet. 2021.
6. Davies M et al. Tirzepatide versus Semaglutide Once Weekly in Patients with Type 2 Diabetes. New England Journal of Medicine. 2021.
7. Nauck MA et al. GLP-1 receptor agonists in the treatment of type 2 diabetes - state-of-the-art. Molecular Metabolism. 2021.
8. Aroda VR et al. Efficacy and Safety of Once-Weekly Semaglutide Versus Once-Daily Insulin Glargine as Add-on to Metformin in Patients With Type 2 Diabetes (SUSTAIN 4). Diabetes Care. 2017.
9. Garvey WT et al. Two-year effects of semaglutide in adults with overweight or obesity: the STEP 5 trial. Nature Medicine. 2022.
10. Rubino DM et al. Effect of Weekly Subcutaneous Semaglutide vs Daily Liraglutide on Body Weight in Adults With Overweight or Obesity Without Diabetes. JAMA. 2022.
11. Frias JP et al. Tirzepatide versus Semaglutide Once Weekly in Patients with Type 2 Diabetes (SURPASS-2). New England Journal of Medicine. 2021.
12. Lingvay I et al. Efficacy and safety of once-weekly semaglutide versus daily canagliflozin as add-on to metformin in patients with type 2 diabetes (SUSTAIN 8). Diabetes Care. 2019.
13. Dahl D et al. Effect of Subcutaneous Tirzepatide vs Placebo Added to Titrated Insulin Glargine on Glycemic Control in Patients With Type 2 Diabetes. JAMA. 2022.
14. FDA Drug Shortages Database. Semaglutide and Tirzepatide Shortage Status. Updated April 2026.

Footer disclaimers

Platform Disclaimer. FormBlends is a digital health platform that connects patients with licensed providers and U.S.-based pharmacies. We do not manufacture, prescribe, or dispense medication directly. All clinical decisions are made by independent licensed providers.

Compounded Medication Notice. Compounded semaglutide and tirzepatide are not FDA-approved. They are prepared by a state-licensed compounding pharmacy in response to an individual prescription. Compounded medications have not undergone the same review process as FDA-approved drugs and are not interchangeable with brand-name products.

Results Disclaimer. Individual results vary. Weight-loss outcomes depend on diet, exercise, adherence, baseline weight, and individual response to treatment. Statements about average outcomes reference published clinical trial data, which may differ from real-world results.

Trademark Notice. Ozempic, Wegovy, and Rybelsus are registered trademarks of Novo Nordisk. Mounjaro and Zepbound are registered trademarks of Eli Lilly and Company. FormBlends is not affiliated with, endorsed by, or sponsored by Novo Nordisk or Eli Lilly and Company.